

## Chinese Clinical Oncology is now indexed by PubMed/MEDLINE: a big step forward

Helen Seliman, Grace S. Li

Editorial Office, AME Publishing Company, Guangzhou 510220, China

Correspondence to: Helen Seliman. Science Editor, Chinese Clinical Oncology, Editorial Office, AME Publishing Company, Guangzhou 510220, China. Email: editor@thecco.net.

Submitted Mar 12, 2015. Accepted for publication Mar 14, 2015.

doi: 10.3978/j.issn.2304-3865.2015.03.03

View this article at: <http://dx.doi.org/10.3978/j.issn.2304-3865.2015.03.03>

We are extremely proud and honored to announce that *Chinese Clinical Oncology* (CCO, Figure 1) is now indexed by MEDLINE database and all articles published in CCO will be searchable in PubMed after the inclusion of MEDLINE, the primary component of PubMed. Not only is this a significant milestone for CCO as an acknowledgment of its influence and dedication to oncology cancer, but also will tremendously advance its continued exploration and further enhance the academic significance in the field.

Launched quarterly in September 2012, CCO publishes articles that describe new findings in the field of oncology, provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. CCO is officially endorsed by Chinese Society of Clinical Oncology (CSCO).

Till now, ten issues of CCO have been published, among which four are focused issues (Table 1). The focused issues that were guest-edited by the leading experts in their field highlight the updated research in a specific field, providing a critical analysis and comprehensive overview of contemporary and at times controversial aspects of the topic. It is expected that these focused issues will allow tremendous progress in our ongoing understanding and sharing of knowledge. The amount of submissions published has increased steadily over the 3 years (Figure 2).

CCO attaches great importance to providing a platform for discussion and experience sharing of clinical oncology research. The special column “Statistics in Oncology





Figure 1 The sample of *Chinese Clinical Oncology* (CCO).

Clinical Trials” in CCO chaired by Prof. Daniel J. Sargent and Prof. Qian Shi from Mayo Clinic has been published in three issues and will be run continuously ([www.thecco.net/post/view/statistics-in-oncology-clinical-trials](http://www.thecco.net/post/view/statistics-in-oncology-clinical-trials)).

Also, more focused issues are coming. The potential topics are listed at Table 2. Among them, the issue on “Clinical Trials in the Genome Era—Study Designs and Endpoints, Practical Considerations” will include overview papers on general statistical and clinical issues, papers highlighting challenges within specific disease types, as well as profiles of selected genome-based trials. The issue on “Lung Cancer” edited by Dr. Jean-pierre Armand and Dr. Ju Liya will feature presentations given in Sino-French 2014 Symposium in Thoracic Oncology to reflect the

**Table 1** The published special issues in *Chinese Clinical Oncology (CCO)*

Publication year	Topic	Guest editor(s)	Affiliation
June 2013	Colorectal Cancer	Daniel Haller	Deenie Greitzer Gastrointestinal Medical Oncology Professor Emeritus, Abramson Cancer Center at the University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
December 2013	Hepatocellular Carcinoma	Ghassan Abou-Alfa	Memorial Sloan-Kettering Cancer Center, New York, USA
June 2014	The Changing World of Drug Development	Christian Dittich	Ludwig Boltzmann Institute for Applied Cancer Research-LB Cluster Translational Oncology, Center for Oncology and Hematology, Kaiser Franz Josef-Spital, Vienna, Austria
September 2014	Systemic Treatment of Cutaneous and Mucosal Melanoma	Antonio Buzaid	D. Chairman, Centro Oncológico Antonio Ermírio de Moraes, São Paulo, Brazil
		Jun Guo	The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China
		Sanjiv Agarwala	Professor of Medicine at Temple University School of Medicine, Chief of Medical Oncology at St. Luke's Hospital & Health Network, Bethlehem, Philadelphia, USA
December 2014	Surgical Oncology	Charles Balch	University of Texas Southwestern Medical Center, Dallas, Texas, USA

**Figure 2** The amount of submissions published in *Chinese Clinical Oncology (CCO)* from 2012 to 2014.

collaborative effort and the cutting-edge technology and research cooperation between China and France and has become part of the 50th anniversary of the Sino-French collaboration.

As stated by prof. Charles M. Balch, the Editor-in-Chief

in *Annals of Surgical Oncology* “It is a large and competitive arena for high quality publications. Nevertheless, I am confident that *CCO* will provide another venue for high quality publications based upon the impressive expansive of research activities in China and will attract excellent publications from investigators in China, elsewhere in Asia, and throughout the world”, we believe this valuable inclusion by MEDLINE will widely promote the dissemination of articles published in our journal to all over the world, eventually benefiting the oncologists’ clinical practices and scientific research and health care for patients.

We deeply thank the distinguished Editors-in-Chief and editorial board members, respectable authors and readers worldwide for their lasting support and contribution.

Thanks to their joint efforts, *CCO* is successfully indexed by MEDLINE now. With more confidence and expectation, *CCO* will continue to work towards a robust platform with increased impact for the education, communication and exploration of the international researchers and clinicians.

**Table 2** The forthcoming issues in *Chinese Clinical Oncology* (CCO)

Topic	Guest editor(s)	Affiliation
Lymphoma	Bruce Cheson	Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, USA
	Jun Zhu	Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
Clinical Trials in the Genome Era—Study Designs and Endpoints, Practical Considerations	Daniel Sargent	Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
	Sumithra Mandrekar	Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
	Axel Grothey	Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Brain Metastasis	Michael Weller	Department of Neurology, University Hospital Zurich, Switzerland
	Matthias Preusser	Comprehensive Cancer Centre Vienna, Medical University of Vienna General Hospital, Vienna, Austria
Lung Cancer	Jean-pierre Armand	Institut Gustave Roussy, Cancer Campus Grand Paris, France
	Ju Liya	Project Coordinator, Special Representative for Relations with China, Gustave Roussy, France
Breast Cancer	Ning Liao	Southern Medical University, Guangzhou 510515, China
	Charles Blach	University of Texas Southwestern Medical Center, Dallas, Texas, USA
Pancreatic Cancer	Eileen M. O'Reilly	Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
Immunotherapy of Cancer	Jon Wigginton	Senior Vice President of Clinical Development, MacroGenics, Inc, University of Michigan, USA
	Bernie Fox	Laboratory of Molecular and Tumor Immunology, EACRI; MMI and Env and Biomolec Systems, Leader, of Tumor Immunology Focus Group, OHSU Cancer Institution, USA
	Wenru Song	Astrazeneca Pharmaceutical, and CAHON, USA
	Shukui Qin	Director of Cancer Center of Chinese PLA, Executive Member of the Asian Clinical Oncology Society (ACOS), Chair of Chair of Chinese Society of Clinical Oncology (CSCO), China
Thoracic Malignancies	Ken O'Byrne	Department of Clinical and Medical Oncology, St James's Hospital and Trinity College, Dublin, Ireland
Esophagus Cancer	David Ilson	Memorial Sloan-Kettering Cancer Center, New York, NY, USA
	Geoff Ku	Memorial Sloan Kettering Cancer Center, Department of Medicine, Gastrointestinal Oncology Service, New York, USA
Biliary Issue	Ghassan Abou-Alfa	Memorial Sloan-Kettering Cancer Center, New York, NY, USA

ACOS, Asian Clinical Oncology Society; CSCO, Chinese Society of Clinical Oncology.

## Acknowledgements

*Disclosure:* The authors declare no conflict of interest.

**Cite this article as:** Seliman H, Li GS. *Chinese Clinical Oncology* is now indexed by PubMed/MEDLINE: a big step forward. *Chin Clin Oncol* 2015;4(1):1. doi: 10.3978/j.issn.2304-3865.2015.03.03